PPAR and its targets have been identified as promising therapeutic targets for type 2 diabetes [7,8].With the rapid advancement of biological and chemical knowledge, docking has reshaped research and expanded avenues for drug applicant identification. This evidence concerns the gene PPARA and type 2 diabetes mellitus.